Data Also Showed That Over a 6 Month Period, Nasacort AQ Did Not Cause
Significant Adrenal Suppression in This Same Age Group
BRIDGEWATER, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting suggests that the intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray may be used safely and effectively to treat children aged 2-5 years old with year-round allergic rhinitis. The same study also showed that during the study, Nasacort AQ did not show a significant effect on adrenal function among a subset of the same patients.
Caused by an allergic reaction to allergens such as house dust, animal dander, or pollen, allergic rhinitis is the most common chronic childhood disease, effecting as many as 40% of all children in the U.S.
A clinical study suggests that Nasacort AQ may present a safe and effective treatment option in children aged 2-5 years with year-round allergic rhinitis
In a multicenter, randomized, double-blind study, Nasacort AQ, given as 1 spray per nostril once daily for 4 weeks, improved combined symptoms of sneezing, nasal itching, discharge, and congestion, compared with placebo in children aged 2-5 years who have had year-round allergic rhinitis for at least one year. Nasacort AQ also showed comparable safety to placebo.
"This study suggests that Nasacort AQ may be used safely and effectively to treat young children who suffer from year-round allergies," said lead investigator Dr. Steven Weinstein of University of California at Irvine College of Medicine.
This study is the first and only randomized, double-blind,
placebo-controlled study designed specifically to investigate both the
efficacy and safety of an intranasal corticosteroid in this very young age
group. A total of 474 patients were randomized to receive either Nasacort
AQ or placebo as 1 spray per nostril once daily for 4 weeks. To particip
'/>"/>
| SOURCE sanofi-aventis Copyright©2007 PR Newswire. All rights reserved |